Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Eyedrops Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 17, 2026, 6:04 PM EDT
Recruiting Phase 2 Interventional

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06686472
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Not listed Phase 2 Interventional

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%, Placebo
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126
View directory record Official record
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 4 Interventional

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

NCT01312402
View directory record Official record
Conditions
Infantile Nystagmus Syndrome
Interventions
topical brinzolamide 1% in 5mL ophthalmic medication, Placebo in 5 mL dispenser
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of a Eye Drop for Eye Allergy

NCT00889330
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
alcaftadine, Placebo
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Fairfield, Ohio • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease

NCT00667004
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ecabet ophthalmic solution, placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

NCT03836664
View directory record Official record
Conditions
Migraine
Interventions
Timolol, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

NCT05528172
View directory record Official record
Conditions
Corneal Edema After Cataract Surgery
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Early Phase 1 Interventional

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

NCT04792580
View directory record Official record
Conditions
Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions
Lifitegrast 5% Ophthalmic Solution, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02831387
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Artesia, California • Kansas City, Missouri • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

NCT01129856
View directory record Official record
Conditions
Dry Eye
Interventions
Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

NCT05759208
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OK-101, Placebo
Drug
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

NCT05314738
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
NXL Energy 1, NXL Energy 2, NXL Energy 3, Sham Treatment
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Dothan, Alabama • Teaneck, New Jersey • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of USB005 in Healthy Volunteers

NCT03615196
View directory record Official record
Conditions
Healthy Volunteers
Interventions
USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 3 Interventional

Phase 3 Study of EBI-005 in Dry Eye Disease

NCT01998802
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Active Comparator EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
45
States / cities
Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 17, 2026, 6:04 PM EDT
Not listed Early Phase 1 Interventional

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

NCT05995392
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Topical spironolactone ophthalmic solution, 0.005 mg/cc, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 17, 2026, 6:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

NCT00586664
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, Bepotastine Besilate Ophthalmic Solution 1.0%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 17, 2026, 6:04 PM EDT